Skip to main content
. 2021 May 27;11(5):104. doi: 10.1038/s41408-021-00495-3

Fig. 3. Initial response assessment with the triplet regimen.

Fig. 3

*C1 D14: Perform bone marrow biopsy; if bone marrow shows <5% blasts and/or <5% cellularity/insufficient sample → Stop venetoclax and FLT3i on D14. **If the C1 D14 bone marrow show >5% blasts → continue venetoclax, FLT3i till D21. @Repeat a C1 D28 bone marrow on all patients to confirm remission. If C1 D28 marrow confirms remission and ANC<0.5 and/or platelet < 50K consider interrupting FLT3i and using neupogen to enhance count recovery.